Finally, to assess the potential therapeutic benefit of counteracting AMPK signaling deficit in GBS, we compared the disease severity in GBS patients with type 2 diabetes treated with AMPK activator metformin and those receiving insulin and/or sulphonylurea derivatives without metformin. Here, INS is linked to type 2 diabetes mellitus.